Cognition Therapeutics, Inc. is a clinical-stage neuroscience company developing oral medications designed to treat neurodegenerative disorders
The sheer number of patients and caregivers affected by the combined burden of Alzheimer’s disease and dementia with Lewy bodies (DLB) is the driving force behind Cognition’s mission to develop safe, effective, easy-to-administer treatment options that slow the progression of these life-altering diseases.
Cognition is advancing the development of an oral medication – zervimesine (also CT1812) – to treat these diseases.
Our Lead Candidate – Zervimesine
Zervimesine (CT1812) is a small-molecule oral therapeutic candidate currently being investigated for the treatment of DLB and Alzheimer’s disease. Preclinical and early clinical data showed that zervimesine blocks the toxic protein oligomers implicated in synaptic damage. We believe by preventing toxic oligomers from binding to synapses, zervimesine protects synaptic integrity and function in patients with neurodegenerative diseases. A simple, once-daily oral therapy, zervimesine has the potential to be an accessible, home-based treatment that can help maintain quality of life and reduce caregiver burden for these patients.
